Downstream Bio-processing Controllers Market (2019-2025)

Downstream bio-processing is a process in biopharmaceutical manufacturing to recover the pure protein from contaminant proteins. The growth in this market is majorly driven by growing demand for biopharmaceuticals, rising adoption of single-use technology (single use bio-processing equipment and consumables), and capacity expansion by biopharmaceutical manufacturers. Further, rising demand form emerging Asia-Pacific and Latin American markets, expected surge in biosimilar production in the U.S., growing demand for personalized medicine, and increase in the support from governments for biopharmaceutical research offer significant growth opportunities for the players operating in the downstream bio-processing controllers market.

With the increasing prevalence of chronic illness across the globe, the biopharmaceuticals have exhibited substantial growth in the overall pharmaceutical market. According to American Pharmaceutical Review - one of the leading journals in the pharmaceutical industry - the percentage of antibody-based products currently under the biologic license application (BLA) or equivalent stage of regulatory submission - accounts for ~67% of all biopharmaceuticals. Also, according to the journal, antibody-based products contribute ~82% of products in phase 3 development and ~90% of products in phase 1 and 2 development. In addition, with the increasing demand, the approval of biopharmaceutical products has increased in recent years. For instance, according to Creative Biolabs, Inc. (a life science company), the number of antibody approval has increased in numbers since past 3-4 years. In 2017, 10 new monoclonal antibodies were approved for commercialization around the world as compared to 3 in 2014. Therefore, with growing demand for bio-pharmaceuticals, the overall production capacity is expected to grow over the coming years, thereby driving the growth of the bioprocessing equipment market including downstream bio-processing controllers.

Growing investments in infrastructure and capacity development, low labor cost, growing adoption of single-use technology, improving adherence to the global manufacturing standards, and increasing regulatory oversight in developing economies are the major reasons for increase in biopharmaceutical production in the emerging Asia-Pacific and Latin American markets. For instance, in November 2015, JHL Biotech (Taiwan) used modular single-use technology – KUBio, prefabricated factory on wheels – offered by GE Healthcare Life Sciences - for construction of its biopharmaceutical facility in Wuhan, China. Further, the increasing approvals of biological entities in emerging economies have attracted the players to invest in bio-manufacturing research and production activities. For instance, in July 2017, Chugai Pharmaceutical Co., Ltd. (Japan) signed a joint research agreement with the National Cancer Center (Japan) - for the “MASTER KEY Project” to promote research and development in the field of rare cancers and genomic medicines. Therefore, owing to aforementioned reasons, the bio-production and related research & development is increasing in emerging economies, thereby driving the demand for downstream bio-processing controllers.